I-Semaglutide umuthi ohliswayo kashukela owakhiwe nguNovo Nordisk ngokwelashwa kwesifo sikashukela sohlobo 2. NgoJuni 2021, i-FDA yavunyelwa i-semaglutide yokumaketha njengesidakamizwa sokunciphisa isisindo (igama lokuhweba legovy). Lo muthi uyi-purtide-efana ne-peptide 1 (gep-1) i-agonist evuthayo engalingisa imiphumela yayo, yehlise indlala yayo, futhi ngaleyo ndlela yehlise ukudla nokudla kwekhalori, ngakho-ke kuyaphumelela ekunciphiseni isisindo.
Ngaphezu kokusetshenziselwa ukwelapha isifo sikashukela sohlobo 2 nokukhuluphala, i-semaglutive nayo itholakele ukuvikela impilo yenhliziyo, ukunciphisa ubungozi bomdlavuza, nosizo lokuyeka ukuphuza. Ngaphezu kwalokho, izifundo ezimbili zakamuva zikhombisile ukuthi i-semaglutive inganciphisa futhi ingozi yesifo sezinso nezifo ezingama-alzheimer.
Ucwaningo lwangaphambilini lukhombisile ukuthi ukulahlekelwa kwesisindo kungadambisa izimpawu zeKnee Osteoarthritis (kufaka phakathi ukukhululeka kobuhlungu). Kodwa-ke, imiphumela yezidakamizwa zokunciphisa isisindo se-glp-1 i-agOnist enjengeSemarlutide emiphumeleni ye-Knee Osteoarthritis kubantu abakhuluphele abakafundwanga ngokuphelele.
Ngo-Okthoba 30, 2024, abacwaningi abavela e-University of Copenhagen naseNovo Nordisk bashicilela iphepha lokucwaninga elinesihloko: Kwake kwaba isonto lamasonto abantu abaningi nge-England Journal of Medicine (Nejm), iphephabhuku eliphakeme lezokwelapha.
Lolu cwaningo lwemitholampilo lubonise ukuthi i-semaglutive inganciphisa kakhulu isisindo futhi inciphise kakhulu izinhlungu ezibangelwa isifo samathambo esihlobene nokukhuluphala (umphumela we-analgesic ulingana ne-opioids), futhi uthuthukise amandla abo okubamba iqhaza kwezemidlalo. Lokhu kungokokuqala ngqa ukuthi uhlobo olusha lokunciphisa umzimba, i-glp-1 receptor agonist, kuqinisekisiwe ukuthi kuphathwe ama-arthritis.
Isikhathi sePosi: Feb-27-2025